Overview

Price chart · mood · technical indicators

VOR

Vor Biopharma Incstock Healthcare

Biotechnology

$14.7130.22%Current Market Mood:Strong Bearish

Market Mood

Price Range (1Y)

$2.62$65.80

Current: $14.71

Idea: EMA

1Y Return

+137.3%

Sharpe 3Y

0.60

Market Comparison

vs Healthcare Sector & Biotechnology Industry

VOR

+30.22%

1Y Performance

Fundamentals

Updated daily after market close

P/E ratio—

EPS (TTM)$-70.500.0% YoY

Profit margin0.0%HEALTHCARE

Market cap$676.5MSmall cap

Wall Street coverage

$37.50median target· current $35.00 (+7.1%)9 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E: —
PEG ratio: —
P/B: 0.66
P/S (TTM): —
EV/EBITDA: -3.09

Profitability & growth

ROE (TTM): -125.4%
Operating margin: 0.0%
Revenue growth YoY: 0.0%
Dividend yield: —
Beta: 1.75

Last earnings

Mar 31, 2026 · Reported $44.50

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

50 articles · sorted by date

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Vor Biopharma Inc

Company profile

Vor Biopharma, Inc., an early stage cell therapy company, develops hematopoietic stem cell (eHSC) therapies designed for cancer patients. The company is headquartered in Cambridge, Massachusetts.

Classification

Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
Country: USA
Currency: USD

Company profile

HQ: 500 BOYLSTON STREET, BOSTON, MA
Fiscal year end: December
Latest quarter: Dec 31, 2025

Market cap$676.5M

Shares outstanding$48.8M

52W high$65.80

52W low$2.62

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer

Overview

VOR

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Vor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Rating of "Moderate Buy" from Brokerages

Vor Biopharma Inc. (NASDAQ:VOR) Short Interest Down 17.3% in April

Vor Biopharma (NASDAQ: VOR) files resale registration for 5.34M shares

Ra capital healthcare fund sells 165,150 Vor Biopharma shares for $2.6m

Vor Biopharma (NASDAQ:VOR) Director Ra Capital Management, L.P. Sells 165,150 Shares

RA Capital fund trims Vor Biopharma (NASDAQ: VOR) stake with 165,150-share sale

Ra Capital sells $10.17 million of Vor Biopharma common stock By Investing.com

RA Capital trims Vor Biopharma (VOR) stake, still owns 19.9%

RA Capital fund trims Vor Biopharma (VOR) stake with 630K-share sale

Vor Biopharma(VOR.US) 10% Shareholder Sells US$10.17 Million in Common Stock

Insider Selling: Vor Biopharma (NASDAQ:VOR) Director Sells 171,963 Shares of Stock

Ra Capital sells $10.17 million of Vor Biopharma common stock

Vor Biopharma (NASDAQ:VOR) Shares Down 4.4% - Here's What Happened

H.C. Wainwright lowers Vor Biopharma price target to $31

Ra Capital Management, L.P. Sells 530,610 Shares of Vor Biopharma (NASDAQ:VOR) Stock

Insider Selling: Vor Biopharma (NASDAQ:VOR) Director Sells 153,735 Shares of Stock

RA Capital reports 19.9% Vor Biopharma (VOR) stake after share sales

RA Capital entities trim Vor Biopharma (VOR) stake with 738K-share open-market sale

Vor Biopharma (NASDAQ:VOR) Director Sells $858,840.44 in Stock

HC Wainwright Has Lowered Expectations for Vor Biopharma (NASDAQ:VOR) Stock Price

About Vor Biopharma Inc

Classification

Company profile

VOR

Market Comparison

VOR Market Analysis

Overview

VOR

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Vor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Rating of "Moderate Buy" from Brokerages

Vor Biopharma Inc. (NASDAQ:VOR) Short Interest Down 17.3% in April

Vor Biopharma (NASDAQ: VOR) files resale registration for 5.34M shares

Ra capital healthcare fund sells 165,150 Vor Biopharma shares for $2.6m

Vor Biopharma (NASDAQ:VOR) Director Ra Capital Management, L.P. Sells 165,150 Shares

RA Capital fund trims Vor Biopharma (NASDAQ: VOR) stake with 165,150-share sale

Ra Capital sells $10.17 million of Vor Biopharma common stock By Investing.com

RA Capital trims Vor Biopharma (VOR) stake, still owns 19.9%

RA Capital fund trims Vor Biopharma (VOR) stake with 630K-share sale

Vor Biopharma(VOR.US) 10% Shareholder Sells US$10.17 Million in Common Stock

Insider Selling: Vor Biopharma (NASDAQ:VOR) Director Sells 171,963 Shares of Stock

Ra Capital sells $10.17 million of Vor Biopharma common stock

Vor Biopharma (NASDAQ:VOR) Shares Down 4.4% - Here's What Happened

H.C. Wainwright lowers Vor Biopharma price target to $31

Ra Capital Management, L.P. Sells 530,610 Shares of Vor Biopharma (NASDAQ:VOR) Stock

Insider Selling: Vor Biopharma (NASDAQ:VOR) Director Sells 153,735 Shares of Stock

RA Capital reports 19.9% Vor Biopharma (VOR) stake after share sales

RA Capital entities trim Vor Biopharma (VOR) stake with 738K-share open-market sale

Vor Biopharma (NASDAQ:VOR) Director Sells $858,840.44 in Stock

HC Wainwright Has Lowered Expectations for Vor Biopharma (NASDAQ:VOR) Stock Price

About Vor Biopharma Inc

Classification

Company profile

VOR

Market Comparison